Immunotherapy in GU Cancers | Specialty

Choosing Among First-Line IO/TKI Combos in RCC: The Affordable Option Is the Winner

November 7th 2020

Combination regimens comprised of immunotherapy and TKI inhibitors have yielded significant benefits in terms of overall survival and progression-free survival with acceptable safety in patients with renal cell carcinoma; however, the cost of these regimens may negate the impact of these advances.

Dr. McGregor the Potential Utility of Cabozantinib/Nivolumab in Advanced RCC

November 7th 2020

Bradley McGregor, MD, discusses the potential utility of the combination of cabozantinib and nivolumab in advanced renal cell carcinoma (RCC).

Dr. Choueiri on the Rationale for the COSMIC-313 Trial in Advanced RCC

November 7th 2020

Toni K. Choueiri, MD, discusses the rationale for the phase 3 COSMIC-313 trial in advanced renal cell carcinoma.

Lenvatinib/Pembrolizumab Shows Promise After PD-1/PD-L1 Inhibition in Metastatic Clear Cell RCC

November 6th 2020

The combination of lenvatinib plus pembrolizumab demonstrated encouraging antitumor activity in patients with metastatic clear cell renal cell carcinoma who had progressed on prior PD-1 or PD-L1 immune checkpoint inhibitor therapy.

Dr. Rini on Choosing Between IO/IO or IO/TKI Combinations in mRCC

November 6th 2020

Brian I. Rini, MD, discusses choosing between combinations of dual immunotherapy and immunotherapy/VEGF TKIs in metastatic renal cell carcinoma.

NABUCCO Trial Pursues Neoadjuvant Nivolumab/Ipilimumab in Advanced Urothelial Cancer

October 22nd 2020

The combination of preoperative nivolumab and ipilimumab demonstrated preliminary feasibility and safety in patients with locoregionally advanced urothelial cancer.

Nivolumab/Ipilimumab Elicits Durable Responses in Refractory Advanced RCC

October 6th 2020

Scott Tykodi, MD, PhD, discusses the FRACTION-RCC study and other novel combinations under exploration for heavily pretreated patients with advanced renal cell carcinoma.

Novel PD-1/PD-L1 Inhibitor Combo Promotes Antitumor Activity in Urothelial Carcinoma

September 18th 2020

The investigational PD-L1 inhibitor BGB-A333 in combination with the PD-1 inhibitor tislelizumab demonstrated marked antitumor activity, durable clinical responses, and a tolerable safety profile in patients with urothelial carcinoma.

Gaining Ground With Immunotherapy in Genitourinary Malignancies

August 20th 2020

Bradley McGregor, MD, discusses some of the recent approaches that have emerged in bladder cancer and renal cell carcinoma, as well as anticipated developments in each field.

Immunotherapies Continue to Show Intriguing Benefit in Cisplatin-Ineligible Metastatic Urothelial Cancer

August 17th 2020

Guru P. Sonpavde, MD, discusses several trials in the field of first-line metastatic urothelial cancer that are testing combinations with gemcitabine/platinum-based therapy followed by maintenance avelumab.

x